companies / kailerarx-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-02 json
| total_raised | 900,000,000900.0M | ○ |
|---|---|---|
| founded | 2024 | |
| hq | Waltham MA | |
| industry | unknown | |
| stage | series-b+ |
Kailera Therapeutics develops next-generation GLP-1 and incretin drugs for obesity and metabolic disease, in-licensing assets from Hansoh Pharma. Patients with obesity and type 2 diabetes are the eventual customer base; clinicians and payers are buyers. Kailera advances clinical trials of KAI-9531 plus follow-on candidates with multi-receptor agonism.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-10-01 | series-b | 600,000,000600.0M | null | ○ |
| fact | status | src |
|---|---|---|
| Series B, $600.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |